Apotex alleged that specific US courtroom judgments and FDA choices discriminated versus it, denied it minimum normal of cure and expropriated its financial investment in pravastatin. Damages sought: US$8 million.Even though a variety of US constituents have expressed sizeable concerns about and opposition on the NAFTA dispute resolution system, it